Morgan Stanley Has Lowered Expectations for Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price cut by analysts at Morgan Stanley from $8.00 to $5.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 3.31% from the stock’s previous close. Several […]
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price cut by analysts at Morgan Stanley from $8.00 to $5.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 3.31% from the stock’s previous close. Several […]
